Diagnostica Medica and Proteomedix, the Swiss cancer diagnostics company, have announced that Proclarix , a new blood test for the management of prostate cancer patients, has been introduced in the routine of the laboratory.
Proclarix is an innovative decision support tool to improve the diagnostic management of individuals with suspect for prostate cancer. "We are pleased to be the first commercial laboratory in Italy to have included Proclarix in our routine," said Dr Paola Bruni, Head of the Diagnostica Medica laboratory, part of the Neuromed Group. "The test, consisting of an algorithm that brings together prostate cancer-specific biomarkers along with other clinical parameters, will be of great help in the management of patients with suspected prostate cancer," she also added.
"The diagnostic path of prostate cancer has now totally changed. It is necessary to be able to distinguish tumours with low aggressiveness from those with high, the latter deserving in-depth analysis such as a biopsy. Proclarix is a great help in this regard," Dr Stefano Pecoraro, Director of the Functional Urology Area of the Neuromed Group, commented.
Prostate cancer is the second most frequent cancer diagnosis made in men and the fifth leading cause of death worldwide. In Italy, more than 40,000 new cases of prostate cancer are diagnosed every year and there are about 7000 deaths related to prostate cancer.
"We are pleased with the commercial partnership with Diagnostica Medica that will allow an increasing number of patients to have access to an examination that can reduce invasive procedures and possible complications related to these," said Dr Maurizio Ballerini, Vice President Market Development EMEA at Proteomedix.
